Remove 2027 Remove Patients Remove Safety
article thumbnail

Why is microbiological testing in medical device manufacturing important?

European Pharmaceutical Review

Importantly, they identify potential sources of microbial contamination and assess their risk to patients. However, the safety and efficacy of these devices can be compromised if they are not appropriately designed, manufactured, and maintained, the authors wrote. Sharma et al. appeared first on European Pharmaceutical Review.

article thumbnail

Eli Lilly reveals plans for new high-tech parenteral manufacturing site

European Pharmaceutical Review

“This state-of-the-art parenteral site with the latest technology will enable us to continue to deliver medicines with safety first and quality always around the world,” stated Edgardo Hernandez, Executive Vice President and President of Eli Lilly’s manufacturing operations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Potential blockbuster drugs to watch in 2023

European Pharmaceutical Review

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. The drug can be used to treat a niche group of patients with high unmet need. Several Phase III trials are now underway.   .

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. We have confirmed this in close to 100 subjects who have swallowed the RP.”

article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

percent through 2027. Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Dave Li, PhD Dave Li is a principal consultant and Clinical Research Physician with KCR.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Meath opened last month.